Sepsis Syndrome
31
3
4
14
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.2%
1 terminated out of 31 trials
93.3%
+6.8% vs benchmark
6%
2 trials in Phase 3/4
14%
2 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (31)
Sepsis: From Syndrome to Personalized Care
Identification of Markers of Poor Clinical Prognosis in Sepsis by Epigenetic Analysis
CT for Personalized Mechanical Ventilation
Diagnostic Accuracy in Sepsis
Analysis of the Evolution of Mortality in an Intensive Care Unit
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department
Mitochondrial DNA as a Biomarker of Sepsis Severity
The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Effect of Immunophenotype on Prognosis of Sepsis
Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Metrology to Enable Rapid and Accurate Clinical Measurements in Acute Management of Sepsis
Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage
Blood Gases Versus Lactate Clearance as an Indicator of Initial Resuscitation in Septic Patients: Comparative Study
Function of Circulating Exosomes in Sepsis-induced Immunosuppression
Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)
Release of Nociceptin From Granulocytes in Sepsis
Predict Sepsis; the Predictive Value of Bedside Measures in the Ambulance
The Efficacy of High-flow Nasal Cannula Oxygen Therapy in Sepsis Patients